Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial

胃肠病学 达克拉塔斯韦 肝细胞癌 肝硬化 随机对照试验 安慰剂
作者
Gregory T. Everson,William J. Towner,M. Davis,David L. Wyles,Ronald Nahass,Paul J. Thuluvath,Kyle Etzkorn,Federico Hinestrosa,Myron J. Tong,Mordechai Rabinovitz,John McNally,Diana M. Brainard,Lingling Han,Brian P. Doehle,John G. McHutchison,Timothy R. Morgan,Raymond T. Chung,Tram T. Tran
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:163 (11): 818-826 被引量:88
标识
DOI:10.7326/m15-1000
摘要

Background Effective, pangenotypic treatments for hepatitis C virus (HCV) infection are needed. Objective To assess the safety and efficacy of sofosbuvir with velpatasvir in patients infected with HCV genotypes 1 to 6. Design Randomized, phase 2, open-label study. (ClinicalTrials.gov: NCT01858766). Setting 48 U.S. sites. Patients 377 treatment-naive noncirrhotic patients. In part A, patients infected with HCV genotypes 1 to 6 were randomly assigned to sofosbuvir, 400 mg, with velpatasvir, 25 or 100 mg, for 12 weeks. In part B, patients with genotype 1 or 2 HCV infection were randomly assigned to sofosbuvir, 400 mg, and velpatasvir, 25 or 100 mg, with or without ribavirin for 8 weeks. Measurements Sustained virologic response at 12 weeks (SVR12). Results In part A, SVR12 rates were 96% (26 of 27) with velpatasvir, 25 mg, and 100% (28 of 28) with velpatasvir, 100 mg, for genotype 1; 93% (25 of 27) in both groups for genotype 3; and 96% (22 of 23) with velpatasvir, 25 mg, and 95% (21 of 22) with velpatasvir, 100 mg, for genotypes 2, 4, 5, and 6. In part B, for genotype 1, SVR12 rates were 87% (26 of 30) with velpatasvir, 25 mg; 83% (25 of 30) with velpatasvir, 25 mg, plus ribavirin; 90% (26 of 29) with velpatasvir, 100 mg; and 81% (25 of 31) with velpatasvir, 100 mg, plus ribavirin. For genotype 2, SVR12 rates were 77% (20 of 26) with velpatasvir, 25 mg; 88% (22 of 25) with velpatasvir, 25 mg, plus ribavirin; 88% (23 of 26) with velpatasvir, 100 mg; and 88% (23 of 26) with velpatasvir, 100 mg, plus ribavirin. Adverse events included fatigue (21%), headache (20%), and nausea (12%). One patient committed suicide. Limitation The study was open-label, no inferential statistics were planned, and sample sizes were small. Conclusion Twelve weeks of sofosbuvir, 400 mg, and velpatasvir, 100 mg, was well-tolerated and resulted in high SVR in patients infected with HCV genotypes 1 to 6. Primary funding source Gilead Sciences.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冷艳的太君完成签到 ,获得积分10
刚刚
16601107082发布了新的文献求助10
刚刚
ccx完成签到,获得积分10
1秒前
李侑勳完成签到,获得积分10
1秒前
1秒前
Hera完成签到,获得积分20
1秒前
细水长流完成签到 ,获得积分10
1秒前
2秒前
slsdianzi完成签到,获得积分10
2秒前
calico完成签到,获得积分10
2秒前
微笑枫完成签到,获得积分10
3秒前
英俊馒头完成签到,获得积分10
3秒前
风趣的寻凝完成签到 ,获得积分10
3秒前
多情的寻真完成签到,获得积分10
3秒前
DOC_XIONG的应助被ale采纳,获得10
3秒前
刻苦以云完成签到 ,获得积分10
4秒前
4秒前
阿飞大师完成签到,获得积分10
4秒前
XPDrake完成签到,获得积分10
4秒前
JL完成签到 ,获得积分10
4秒前
TheDing完成签到,获得积分10
5秒前
武陵济世完成签到,获得积分10
5秒前
horse888完成签到,获得积分10
6秒前
风不言喻完成签到,获得积分10
6秒前
Ya_Yen完成签到,获得积分10
6秒前
zjh完成签到 ,获得积分10
7秒前
8秒前
27完成签到 ,获得积分10
9秒前
9秒前
秋月明完成签到,获得积分10
9秒前
科研通AI6.2的应助被武陵济世采纳,获得10
9秒前
墨z完成签到 ,获得积分10
10秒前
小亮哈哈完成签到,获得积分0
10秒前
奥特曼发布了新的文献求助30
10秒前
小水蜜桃完成签到 ,获得积分10
11秒前
11秒前
xiaoxu小徐完成签到 ,获得积分10
11秒前
娃哈哈完成签到,获得积分10
12秒前
顾志成发布了新的文献求助10
13秒前
周海涛发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159151
求助须知:如何正确求助?哪些是违规求助? 9554617
关于积分的说明 21719982
捐赠科研通 7748814
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552091
邀请新用户注册赠送积分活动 2471436